Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LCK
REST API REST API
Homo sapiens
LCK is differentially expressed in 266 experiments: 112 organism parts: bone marrow, thymus, ... (110 more);, 218 disease states: normal, prostate carcinoma, ... (216 more);, 125 cell types 457 cell lines 30 compound treatments and 67 other conditions.
Orthologs Lck (Rattus norvegicus)   Q3ZCM0_BOVIN (Bos taurus)   Lck (Mus musculus)   lck (Danio rerio)   lck (Xenopus laevis)   LCK (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, response to hydrogen peroxide, plasma membrane, endocytic vesicle, protein binding, apoptosis, SH2 domain binding, cytoplasm, pericentriolar material, peptidyl-tyrosine phosphorylation, Golgi apparatus, protein serine/threonine phosphatase activity, activation of caspase activity, protein tyrosine kinase activity, blood coagulation, membrane raft, protein tyrosine phosphatase activity, hemopoiesis, ATP binding, induction of apoptosis, cell surface receptor linked signaling pathway, protein kinase binding, response to zinc ion, aging, nucleotide binding, response to metal ion, protein serine/threonine kinase activity, response to drug, protein C-terminus binding, non-membrane spanning protein tyrosine kinase activity, release of sequestered calcium ion into cytosol, response to mechanical stimulus, protein kinase activity, viral reproduction, T cell receptor signaling pathway, positive regulation of T cell activation, antigen binding, cellular zinc ion homeostasis, positive regulation of uterine smooth muscle contraction, B cell receptor signaling pathway, leukocyte migration, ATPase binding, peptidyl-tyrosine dephosphorylation, positive regulation of gamma-delta T cell differentiation, positive regulation of tyrosine phosphorylation of Stat5 protein, interspecies interaction between organisms, glycoprotein binding, regulation of T cell receptor signaling pathway, protein complex binding, T cell costimulation, CD4 receptor binding, T cell differentiation, platelet activation, positive regulation of T cell receptor signaling pathway, protein autophosphorylation, protein phosphorylation, regulation of lymphocyte activation, regulation of defense response to virus by virus, CD8 receptor binding, phosphatidylinositol 3-kinase binding
InterPro Term SH2, SH3_domain, Prot_kinase_cat_dom, SH3_2, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P06239, Q573B4, B3KUV3, E9PQ10, E7EN21, E9PAP0, E9PI33, E9PJ92, E9PKQ8, F8W6B9
Search EB-eye ENSG00000182866
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-7224, E-MEXP-433, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (33 experiments)

Factor Value U/D Experiments
SW480
4
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
SNU1
2
E-MTAB-37, E-GEOD-15460
AGS
2
E-GEOD-15460, E-MTAB-37
HL-60
2
E-GEOD-96, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-GEOD-5258, E-MEXP-2034
451 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-120, E-GEOD-20677, E-GEOD-2822, ... (56 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-TABM-145, E-MTAB-25, E-GEOD-6740
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
centroblast
2
E-TABM-702, E-GEOD-15271
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
119 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (55 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-MTAB-62, E-MEXP-2034, E-GEOD-3868, E-MTAB-37 ... (5 experiments)
chronic lymphocytic leukemia
3
E-GEOD-2466, E-GEOD-6691, E-MTAB-37
sarcoma
2
E-GEOD-2719, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
cervical carcinoma
2
E-MTAB-62, E-GEOD-5823
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
212 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-697, E-TABM-782, E-GEOD-3720, ... (26 experiments)

Factor Value U/D Experiments
none
4
9
E-GEOD-5824, E-MEXP-1958, E-GEOD-7400, E-GEOD-3306, E-GEOD-412, ... (13 experiments)
lipopolysaccharide
1
2
E-GEOD-3720, E-MEXP-1958, E-TABM-868
resveratrol
1
E-TABM-782
BCR/ABL1
1
1
E-GEOD-15811
U0126
1
E-GEOD-697
NaOH
1
1
E-MEXP-2590
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-20847, E-MTAB-108

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, E-MEXP-1741, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-974, E-GEOD-2466, ... (32 experiments)

Infection
studied in E-MEXP-561, E-GEOD-980, E-GEOD-512

Injury
studied in E-GEOD-19743

Irradiate
studied in E-MEXP-2177

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-15799, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.478 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM